0001193125-21-300045.txt : 20211015 0001193125-21-300045.hdr.sgml : 20211015 20211015161611 ACCESSION NUMBER: 0001193125-21-300045 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20211015 DATE AS OF CHANGE: 20211015 EFFECTIVENESS DATE: 20211015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Strongbridge Biopharma plc CENTRAL INDEX KEY: 0001634432 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981130690 STATE OF INCORPORATION: L2 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-37569 FILM NUMBER: 211326248 BUSINESS ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 BUSINESS PHONE: (610) 254-9200 MAIL ADDRESS: STREET 1: 900 NORTHBROOK DRIVE, SUITE 200 CITY: TREVOSE STATE: PA ZIP: 19053 FORMER COMPANY: FORMER CONFORMED NAME: Cortendo AB DATE OF NAME CHANGE: 20150219 15-12B 1 d226700d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-37569

 

 

STRONGBRIDGE BIOPHARMA PLC

(Exact name of registrant as specified in its charter)

 

 

900 Northbrook Drive, Suite 200

Trevose, Pennsylvania 19053

(610) 254-9200

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

ORDINARY SHARES, PAR VALUE $0.01 PER SHARE

(Title of each class of securities covered by this Form)

NONE

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

  

Rule 12g-4(a)(1)

   

☒

   
  

Rule 12g-4(a)(2)

   

☐

   
  

Rule 12h-3(b)(1)(i)

   

☒

   
  

Rule 12h-3(b)(1)(ii)

   

☐

   
  

Rule 15d-6

   

☐

   
  

Rule 15d-22(b)

   

☐

   

Approximate number of holders of record as of the certification or notice date: 1

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Strongbridge Biopharma plc has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

DATE: October 15, 2021     BY:  

/s/ Steven M. Pieper

      Steven M. Pieper
      Chief Financial Officer